Rep. Gilbert Ray Cisneros Jr. (D-CA) Sells HALO Stock
Congressman Gilbert Ray Cisneros Jr. sold shares of Halozyme Therapeutics valued between $1,001 and $15,000 on September 29, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) sold between $1,001 and $15,000 of Halozyme Therapeutics, Inc. ($HALO) stock on September 29, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $HALO is down 1.6% after 1 week and up 9.2% to date (from the $111.56 close on Sep 29, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Halozyme Therapeutics, Inc. ($HALO) | Sell | Sep 29, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
HALO
Halozyme Therapeutics, Inc.
Key Points
- On September 29, 2026, Gilbert Ray Cisneros Jr. sold shares of Halozyme Therapeutics, Inc. valued between $1,001 and $15,000.
- As of October 16, 2026, Halozyme's stock recently traded around $121.49, above its 50-day moving average by 12.3%.
- Halozyme Therapeutics has a market cap of about $13.83 billion and is expected to report earnings on November 2, 2026.
Get $HALO trade alerts by text
We text you when insiders, Congress or big funds trade $HALO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Halozyme Therapeutics, Inc. alert may contain errors. Disclosures
Congressman Gilbert Ray Cisneros Jr. sold shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) valued between $1,001 and $15,000 on September 29, 2026. The transaction was reported on October 12, 2026, and took place while the stock was performing well in the market.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
Inside Gilbert Ray Cisneros Jr.'s Trade
Gilbert Ray Cisneros Jr., a Democrat representing California's 31st district in the House, made this sale as part of his periodic stock transactions.
Other Institutional Activity in Halozyme Therapeutics
Several institutional investors have also recently adjusted their positions in Halozyme Therapeutics. Blackrock Inc. grew its holdings by 6,632 shares, bringing its total to about 13,271,095 shares worth approximately $1.62 billion. Vanguard Capital Management LLC added 80,122 shares, increasing its stake to 5,351,312 shares valued at about $652 million. State Street Corporation increased its holdings by 241,467 shares, totaling 5,179,434 shares worth around $631 million. Conversely, Invesco Ltd. reduced its position by 834,625 shares, ending with 3,177,997 shares valued at about $387 million.
Halozyme Therapeutics, Inc. Stock Holds Steady
As of October 16, 2026, Halozyme's stock was recently trading around $121.49. This price is above its 50-day moving average of about $108.19 and its 200-day average of about $80.34, indicating strong recent performance. However, the stock is still below its 52-week high of $122.45 by about 0.8%. Investors are closely watching the upcoming earnings report, which is set for November 2, 2026.
Recent Earnings
Halozyme Therapeutics reported trailing twelve-month revenue of approximately $1.66 billion. The company has shown impressive revenue growth year-over-year at 47.7%. Additionally, it has a net margin of 24.9% and a return on equity of 173.7%, reflecting strong operational efficiency. The next earnings report will provide further insights into the company’s performance.
Insider Buying and Selling at Halozyme Therapeutics, Inc.
In recent months, several insiders have sold shares of Halozyme. On August 10, 2026, Director Bernadette M. Connaughton sold 1,626 shares at an average price of $102.80, totaling about $167,153. CEO Helen I. Torley sold 60,000 shares on both August 19 and September 11, 2026, with the combined value of these transactions exceeding $6.27 million. Director Matthew L. Posard sold 18,996 shares on September 16, 2026, valued at approximately $2.05 million. These sales indicate active management among the company’s leadership.
Analysts Set New Price Targets
On October 13, 2026, TD Cowen maintained its Buy rating on Halozyme Therapeutics with a new price target of $130. Citizens also maintained a Market Outperform rating with a target of $93, while Wells Fargo kept an Equal-Weight rating with a target of $95. The consensus among analysts remains a Buy rating, with a mean price target of approximately $108.78.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on researching and developing proprietary enzymes and devices that enhance the delivery of injectable biologics and other therapeutic molecules. The company’s innovative approaches are critical in the healthcare sector, especially in the biotechnology industry.
Bottom Line
Investors should keep an eye on Halozyme’s upcoming earnings report on November 2, 2026, which is expected to provide more clarity on the company's financial health. Additionally, monitoring insider trading activity and institutional investment trends can offer insights into market sentiment surrounding Halozyme Therapeutics.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $HALO (Sep 29, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts